lower cost equivalent "pharmaceutical" will substitute for the Vascepa for whatever indication under Medicare (X% of market). No matter what the script says.
Period.
this is the problem with Amarin's market building, too slow and now a "decay" due to early generics entry.
would a BO now not deliver more value to shareholders, not to mention that to cut all admin, "marketing" (which all would be an incremental for the Buyer operation) and parachuting our wonderful executives, then make Vascepa a real goldmine?
Market Data 
Markets 
AI
